MCID: BRK010
MIFTS: 71

Burkitt Lymphoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Burkitt Lymphoma

MalaCards integrated aliases for Burkitt Lymphoma:

Name: Burkitt Lymphoma 53 12 49 55 71 36 28 13 51 41 14 37 69
Burkitt's Lymphoma 37 12 72 49
Bl 53 49 71
Small Non-Cleaved Cell Lymphoma, Burkitt's Type 12
Malignant Lymphoma, Burkitt's Type 12
Small Non-Cleaved Cell Lymphoma 55
Lymphoma, Small Noncleaved-Cell 69
Burkitt's Tumor or Lymphoma 12
Burkitt Lymphoma/leukaemia 12
Burkitt's Tumor 12
Burkitt Tumor 71

Characteristics:

Orphanet epidemiological data:

55
burkitt lymphoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Africa),1-9/1000000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

53
Inheritance:
isolated cases

Miscellaneous:
accounts for 30-50% of lymphomas in children
accounts for 1-2% of lymphomas in adults
three distinct clinical forms - endemic (equatorial africa), sporadic, and immunodeficiency-associated (e.g., hiv infection)


HPO:

31
burkitt lymphoma:
Inheritance sporadic


Classifications:



External Ids:

OMIM 53 113970
Disease Ontology 12 DOID:8584
ICD10 32 C83.7 C83.70
ICD9CM 34 200.2
MeSH 41 D002051
NCIt 46 C2912 C7400
Orphanet 55 ORPHA543
MESH via Orphanet 42 D002051 D008228
UMLS via Orphanet 70 C0006413 C0079770
ICD10 via Orphanet 33 C83.7
MedGen 39 C0006413
KEGG 36 H00008
UMLS 69 C0006413

Summaries for Burkitt Lymphoma

NIH Rare Diseases : 49 Burkitt lymphoma (BL) is a very fast-growing type of cancer. It is a form of B-cellnon-Hodgkin's lymphoma. There are 3 recognized forms of BL: Endemic (African) - the most common form, found mainly in central Africa, where it is associated with the Epstein Barr virus (EBV). It is most common in children. This form often manifests as enlargement of the jaw or facial bones. Sporadic - a rarer form, seen in all parts of the world, that often develops in the abdomen with bone marrow involvement. The kidneys, ovaries, breasts or other organs may also be involved. This form commonly affects children and young adults. Immunodeficiency-associated - occurs primarily in people with HIV infection, and less commonly in people with other immunodeficiency disorders or recipients of organ transplants. Signs and symptoms may differ depending on the form of BL and the organs or body systems involved. When it spreads, weakness and fatigue often develop. Lymphoma cells may build up in the lymph nodes and other organs, causing swelling. Central nervous system involvement is possible with all forms of BL, particularly when there is advanced-stage disease.The exact cause of BL is not known. EBV infection appears to play a role in virtually all cases of endemic (African) BL, and a minority of sporadic and immunodeficiency-associated BL. While acquired (not inherited) genetic changes involving the MYC gene and other genes are present within BL cancer cells, it is unclear what causes these genetic changes to occur. Without timely treatment, BL is rapidly fatal. Treatment involves intensive chemotherapy, which includes chemotherapy to the fluid surrounding the brain and spinal cord. The majority of people treated with aggressive therapy achieve long-term remission. Last updated: 9/25/2017

MalaCards based summary : Burkitt Lymphoma, also known as burkitt's lymphoma, is related to leukemia, acute lymphoblastic 3 and diffuse large b-cell lymphoma, and has symptoms including abdominal pain, nausea and vomiting and hyperuricemia. An important gene associated with Burkitt Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Bexxar and Erivedge have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are Decreased viability in esophageal squamous lineage and shRNA abundance <= 50%

Disease Ontology : 12 A mature B-cell neoplasm of B-cells found in the germinal center.

OMIM : 53 Burkitt lymphoma is a rare, aggressive B-cell lymphoma that accounts for 30 to 50% of lymphomas in children but only 1 to 2% of lymphomas in adults (Harris and Horning, 2006). It results from chromosomal translocations that involve the MYC gene (190080) and either the lambda or the kappa light chain immunoglobulin genes (147220, 147200). Burkitt lymphoma is causally related to the Epstein-Barr virus (EBV), although the pathogenetic mechanisms are not clear. (113970)

UniProtKB/Swiss-Prot : 71 Burkitt lymphoma: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass.

Wikipedia : 72 Burkitt lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal... more...

Related Diseases for Burkitt Lymphoma

Diseases related to Burkitt Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 3 32.4 CXCR5 DNTT PAX5
2 diffuse large b-cell lymphoma 30.9 BCL6 MYC PAX5
3 lymphoma 30.5 BAX BCL6 BCL7A BCL7B CXCL13 CXCR5
4 acquired immunodeficiency syndrome 30.1 BCL6 CD40LG IFNA1 MYC
5 composite lymphoma 29.7 BCL6 PAX5 SOX11
6 myeloma, multiple 29.3 CCND3 CD40 CD40LG MYC
7 b-cell lymphomas 29.2 AICDA BAX BCL6 CCND3 CD40 MS4A1
8 common variable immunodeficiency 28.7 AICDA CD40 CD40LG CR2 MS4A1 SH2D1A
9 follicular lymphoma 28.1 AICDA BCL6 CCND3 CD40 CR2 CXCR5
10 small non-cleaved cell lymphoma 12.6
11 bare lymphocyte syndrome, type ii 11.9
12 bare lymphocyte syndrome, type i 11.7
13 childhood ovarian cancer 11.1
14 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.6 BCL6 CXCR5
15 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 BCL6 MYC
16 neurosyphilis 10.5 CXCL13 CXCR5
17 kyasanur forest disease 10.5 CD40LG IFNA1
18 fasciolopsiasis 10.4 CD40LG IFNA1
19 angioimmunoblastic t-cell lymphoma 10.4 BCL6 CXCL13
20 light fixation seizure syndrome 10.4 CD40 CD40LG
21 nodular lymphocyte predominant hodgkin lymphoma 10.4 BCL6 PAX5
22 intraocular lymphoma 10.4 BCL6 CXCR5 PAX5
23 cryoglobulinemia, familial mixed 10.3 CD40LG IFNA1
24 selective immunoglobulin deficiency disease 10.3 CD40LG SH2D1A
25 immunodeficiency with hyper-igm, type 4 10.3 AICDA CD40 CD40LG
26 hyperimmunoglobulin syndrome 10.3 AICDA CD40 CD40LG
27 ovarian lymphoma 10.3 CR2 MYC
28 cd40 ligand deficiency 10.3 AICDA CD40 CD40LG
29 immunodeficiency with hyper-igm, type 3 10.3 AICDA CD40 CD40LG
30 immunodeficiency with hyper-igm, type 1 10.3 AICDA CD40 CD40LG
31 leukemia 10.2
32 precursor t-cell acute lymphoblastic leukemia 10.2 BAX DNTT MYC
33 dysgammaglobulinemia 10.2 CD40LG SH2D1A
34 pfeiffer syndrome 10.2 CD40LG CR2 SH2D1A
35 agammaglobulinemia 10.2 CD40LG CR2 SH2D1A
36 leukemia, acute lymphoblastic 10.1 BAX DNTT PAX5
37 immunodeficiency with hyper-igm, type 2 10.1 AICDA BCL6 CD40 CD40LG
38 t-cell/histiocyte rich large b cell lymphoma 10.1 BCL6 CR2
39 lung lymphoma 10.1 BCL6 CD40LG CR2 PAX5
40 lymphoblastic leukemia 10.1
41 lymphoma, mucosa-associated lymphoid type 10.1 BCL6 CD40 CD40LG CXCL13 CXCR5
42 intussusception 10.0
43 malaria 10.0
44 immune deficiency disease 10.0 CD40 CD40LG SH2D1A
45 reticulosarcoma 10.0 BCL6 CCND3 PAX5
46 aging 10.0
47 bladder lymphoma 9.9 CR2 PAX5
48 lymphoma, hodgkin, classic 9.9 BCL6 CD40 MS4A1 PAX5
49 waldenstrom macroglobulinemia 9.9 CD40 CD40LG MS4A1 PAX5
50 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 9.9

Graphical network of the top 20 diseases related to Burkitt Lymphoma:



Diseases related to Burkitt Lymphoma

Symptoms & Phenotypes for Burkitt Lymphoma

Symptoms via clinical synopsis from OMIM:

53
Neoplasia:
burkitt lymphoma (b-cell lymphoma)
jaw and kidney tumor (endemic form)
ileal, cecal, ovarian, and breast tumors, occasionally (endemic form)
abdominal tumors (immunodeficiency-associated form)
monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm
more
LaboratoryAbnormalities:
elevated lactate dehydrogenase
elevated uric acid
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin lambda light chain ( , 22q11.2) locus
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin kappa light chain ( , 2p12) locus
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin heavy chain ( , 14q32) locus


Clinical features from OMIM:

113970

Human phenotypes related to Burkitt Lymphoma:

55 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 55 31 occasional (7.5%) Occasional (29-5%) HP:0002027
2 nausea and vomiting 55 31 occasional (7.5%) Occasional (29-5%) HP:0002017
3 hyperuricemia 55 31 frequent (33%) Frequent (79-30%) HP:0002149
4 abnormality of the ovary 55 31 occasional (7.5%) Occasional (29-5%) HP:0000137
5 intestinal obstruction 55 31 occasional (7.5%) Occasional (29-5%) HP:0005214
6 abnormality of the pancreas 55 31 occasional (7.5%) Occasional (29-5%) HP:0001732
7 gastrointestinal hemorrhage 55 31 occasional (7.5%) Occasional (29-5%) HP:0002239
8 abnormality of the spleen 55 31 occasional (7.5%) Occasional (29-5%) HP:0001743
9 abnormal lactate dehydrogenase activity 55 31 frequent (33%) Frequent (79-30%) HP:0045040
10 abnormality of the liver 55 31 occasional (7.5%) Occasional (29-5%) HP:0001392
11 abnormality of bone marrow cell morphology 55 31 frequent (33%) Frequent (79-30%) HP:0005561
12 abnormality of the lymph nodes 55 31 occasional (7.5%) Occasional (29-5%) HP:0002733
13 neoplasm of the oral cavity 55 31 frequent (33%) Frequent (79-30%) HP:0100649
14 decreased number of cd4+ t cells 55 Occasional (29-5%)
15 burkitt lymphoma 31 HP:0030080
16 decreased proportion of cd4-positive t cells 31 occasional (7.5%) HP:0005407

GenomeRNAi Phenotypes related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.65 AICDA BCL6 BCL7A BCL7B CCND3 CXCR5
2 shRNA abundance <= 50% GR00343-S 9.32 AICDA BCL7A BCL7B CD40 CXCR5 DNTT

MGI Mouse Phenotypes related to Burkitt Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 AICDA BAX BCL6 CCND3 CD40 CD40LG
2 immune system MP:0005387 9.86 CD40 CD40LG CR2 CXCL13 CXCR5 DNTT
3 normal MP:0002873 9.32 AICDA BCL6 CCND3 CD40 CXCR5 DNTT

Drugs & Therapeutics for Burkitt Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bexxar 17 45 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
2
Erivedge 17 45 VISMODEGIB Genentech January 2012

Drugs for Burkitt Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
13
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
14
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
15 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
16
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
17
Asparaginase Approved, Investigational Phase 4,Phase 3,Phase 2 9015-68-3
18
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-81-3 30323
19
Teniposide Approved Phase 4,Phase 2,Phase 1 29767-20-2 34698
20
Thioguanine Approved Phase 4,Phase 3,Phase 2 154-42-7 2723601
21 Cetylpyridinium Approved Phase 4 7773-52-6
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
24
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 31703
25 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1 0
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
38 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 711)

# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
6 Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis Recruiting NCT03219840 Phase 4 CPC;Placebo
7 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4 Tenofovir
8 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
9 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
12 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
13 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
14 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
15 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
16 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
17 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
19 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
20 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
21 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
22 Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Completed NCT00838214 Phase 2, Phase 3 budesonide;prednisone
23 Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
24 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
25 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
26 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
27 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
28 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
29 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
30 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
31 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
32 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
33 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
34 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
36 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
37 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
38 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
39 Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
40 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
41 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
42 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
43 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
44 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
45 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
46 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
47 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
48 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
49 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
50 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3

Search NIH Clinical Center for Burkitt Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burkitt Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: burkitt lymphoma

Genetic Tests for Burkitt Lymphoma

Genetic tests related to Burkitt Lymphoma:

# Genetic test Affiliating Genes
1 Burkitt Lymphoma 28 MYC

Anatomical Context for Burkitt Lymphoma

MalaCards organs/tissues related to Burkitt Lymphoma:

38
B Cells, Bone, Bone Marrow, T Cells, Kidney, Breast, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burkitt Lymphoma:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Burkitt Lymphoma

Articles related to Burkitt Lymphoma:

(show top 50) (show all 312)
# Title Authors Year
1
Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients. ( 29415639 )
2018
2
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
3
Molecular and Cytogenetic Studies in a Child with Burkitt Lymphoma and Ataxia-Telangiectasia Syndrome Harboring MYC Overexpression and Partial Trisomy 8. ( 29071822 )
2018
4
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. ( 29209924 )
2018
5
The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. ( 29295643 )
2018
6
MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells. ( 29318382 )
2018
7
Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda. ( 29248801 )
2018
8
In vitro evaluation of the enantiomeric R- and S-1,1'-binaphthyl-2,2'-diaminodichlorido-Pt(ii) complexes in human Burkitt lymphoma cells: emphasis on cellular accumulation, cytotoxicity, DNA binding, and ability to induce apoptosis. ( 29333543 )
2018
9
False-Positive 18F-FDG PET/CT Due to Filgrastim That Induced Extramedullary Liver Hematopoiesis in a Burkitt Lymphoma. ( 29401143 )
2018
10
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. ( 28619753 )
2017
11
Genomic analysis of adult Burkitt lymphoma. ( 29051155 )
2017
12
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. ( 28507339 )
2017
13
The role of traditional healers in the diagnosis and management of Burkitt lymphoma in Cameroon: understanding the challenges and moving forward. ( 28399870 )
2017
14
Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. ( 28474336 )
2017
15
Assessment of the Combined Effect of Epstein-Barr Virus and<i>Plasmodium falciparum</i>Infections on Endemic Burkitt Lymphoma Using a Multiplex Serological Approach. ( 29123514 )
2017
16
Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. ( 28523628 )
2017
17
Incomplete Miller-Fisher Syndrome with Advanced Stage Burkitt Lymphoma. ( 28601853 )
2017
18
Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan. ( 28079574 )
2017
19
Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. ( 28932644 )
2017
20
Burkitt lymphoma. ( 28508391 )
2017
21
Intestinal Burkitt lymphoma in a patient with coeliac disease. ( 28363349 )
2017
22
High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma. ( 29296767 )
2017
23
RALE051: a novel established cell line of sporadic Burkitt lymphoma. ( 28893133 )
2017
24
Silent presentation of multiple metastasis Burkitt lymphoma in a child: A case report and review of the literature. ( 28700504 )
2017
25
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
26
FAMLF is a target of miR-181b in Burkitt lymphoma. ( 28492808 )
2017
27
Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment. ( 28714257 )
2017
28
Viral driven epigenetic events alter the expression of cancer-related genes in Epstein-Barr-virus naturally infected Burkitt lymphoma cell lines. ( 28724958 )
2017
29
Burkitt Lymphoma in Adult With Atypical Clinical Presentation Primarily Involving the Oral Soft Tissue. ( 28328599 )
2017
30
Primary gastric Burkitt lymphoma: a rare cause of life-threatening haematemesis. ( 28830898 )
2017
31
The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. ( 28427156 )
2017
32
Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi. ( 28680947 )
2017
33
Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells. ( 28651105 )
2017
34
High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. ( 29296973 )
2017
35
Primary Burkitt lymphoma of the supraglottic larynx: a case report and review of the literature. ( 28279203 )
2017
36
EBVa89BARTa896a893p and cellular microRNAa89197 compromise the immune defense of host cells in EBVa89positive Burkitt lymphoma. ( 28259992 )
2017
37
Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma. ( 28400759 )
2017
38
The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS. ( 29272887 )
2017
39
Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature. ( 28454254 )
2017
40
Burkitt Lymphoma of the Duodenum. ( 29279519 )
2017
41
In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study. ( 28623395 )
2017
42
Complete progressive ophthalmoplegia and numb chin syndrome, the first clinical manifestations of a lethal abdominal Burkitt lymphoma. ( 28890232 )
2017
43
ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma. ( 28331227 )
2017
44
Gastric Burkitt lymphoma: A case report and literature review. ( 29245266 )
2017
45
Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. ( 28508718 )
2017
46
Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. ( 28792266 )
2017
47
Structure and diversification of immunoglobulin genes in African Burkitt lymphoma. ( 29296766 )
2017
48
Immune Hemolytic Anemia (Paroxysmal Cold Hemoglobinuria) Preceding Burkitt Lymphoma in a 12-Year-Old Child. ( 27879544 )
2017
49
Burkitt lymphoma and cavernous sinus syndrome with breast uptake on 18F-FDG-PET/CT: A case report. ( 29145302 )
2017
50
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. ( 29371955 )
2017

Variations for Burkitt Lymphoma

ClinVar genetic disease variations for Burkitt Lymphoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MYC NM_002467.5(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 GRCh37 Chromosome 8, 128750677: 128750677
2 MYC NM_002467.5(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 GRCh37 Chromosome 8, 128750765: 128750765
3 MYC NM_002467.5(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 GRCh37 Chromosome 8, 128750625: 128750625
4 MYC NM_002467.5(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 GRCh37 Chromosome 8, 128750683: 128750683

Cosmic variations for Burkitt Lymphoma:

9 (show all 33)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43965 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.734G>C p.G245A 9
2 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.742C>T p.R248W 9
3 COSM10725 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.701A>G p.Y234C 9
4 COSM44103 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.737T>A p.M246K 9
5 COSM43565 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.857A>G p.E286G 9
6 COSM43689 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.482C>T p.A161V 9
7 COSM10777 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.715A>G p.N239D 9
8 COSM45844 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.274C>G p.P92A 9
9 COSM36146 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.391C>A p.Q131K 9
10 COSM5203 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.496G>C p.V166L 9
11 COSM5151 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1003C>T p.R335* 9
12 COSM5227 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.182A>T p.H61L 9
13 COSM37032 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1937A>G p.Y646C 9
14 COSM12513 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.298G>T p.A100S 9
15 COSM21825 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1229T>C p.V410A 9
16 COSM21827 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.3161C>G p.P1054R 9
17 COSM21826 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.2572T>C p.F858L 9
18 COSM5702591 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 3
19 COSM28746 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 3
20 COSM28747 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 3
21 COSM28749 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 3
22 COSM28748 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 3
23 COSM28750 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 3
24 COSM5702574 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 3
25 COSM5702592 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 3
26 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 1
27 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 1
28 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 1
29 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 1
30 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 1
31 COSM21829 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8138G>A p.R2713K 1
32 COSM22488 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8494C>T p.R2832C 1
33 COSM21828 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2932T>C p.S978P 1

Copy number variations for Burkitt Lymphoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13309 1 150547027 150552214 Copy number MCL1 Burkitt''s lymphoma
2 17456 1 142870000 177000000 Gain BCA2 Burkitt''s lymphoma
3 17457 1 142870000 177000000 Gain BCL9 Burkitt''s lymphoma
4 17458 1 142870000 177000000 Gain LHX4 Burkitt''s lymphoma
5 17459 1 142870000 177000000 Gain PIAS3 Burkitt''s lymphoma
6 20085 1 15300000 212100000 Insertion NOTCH2 Burkitt''s lymphoma
7 22188 1 166155454 171863618 Gain FASLG Burkitt''s lymphoma
8 25990 1 195253751 195672280 Gain PTPRC Burkitt''s lymphoma
9 26526 1 200970000 201360000 Gain LRRN5 Burkitt''s lymphoma
10 26527 1 200970000 201360000 Gain MDM4 Burkitt''s lymphoma
11 26528 1 200970000 201360000 Gain PIK3C2B Burkitt''s lymphoma
12 26529 1 200970000 201360000 Gain PLEKHA6 Burkitt''s lymphoma
13 26530 1 200970000 201360000 Gain PPP1R15B Burkitt''s lymphoma
14 29698 1 23457835 23714048 Loss E2F2 Burkitt''s lymphoma
15 30116 1 240240000 241350000 Gain ADSS Burkitt''s lymphoma
16 30117 1 240240000 241350000 Gain AKT3 Burkitt''s lymphoma
17 30118 1 240240000 241350000 Gain C1orf100 Burkitt''s lymphoma
18 30119 1 240240000 241350000 Gain C1orf101 Burkitt''s lymphoma
19 30120 1 240240000 241350000 Gain C1orf121 Burkitt''s lymphoma
20 30121 1 240240000 241350000 Gain FAM36A Burkitt''s lymphoma
21 30122 1 240240000 241350000 Gain HNRPU Burkitt''s lymphoma
22 30123 1 240240000 241350000 Gain LOC440742 Burkitt''s lymphoma
23 30124 1 240240000 241350000 Gain ZNF238 Burkitt''s lymphoma
24 42609 10 36983732 37133784 Loss Burkitt''s lymphoma
25 48364 11 1 32410000 Loss FANCF Burkitt''s lymphoma
26 48365 11 1 32410000 Loss PLEKHA7 Burkitt''s lymphoma
27 49723 11 110620000 110810000 Gain C11orf53 Burkitt''s lymphoma
28 49724 11 110620000 110810000 Gain POU2AF1 Burkitt''s lymphoma
29 50222 11 115828212 118580638 Gain Burkitt''s lymphoma
30 50968 11 120700000 134452384 Deletion Burkitt''s lymphoma
31 51055 11 122263650 134452384 Loss Burkitt''s lymphoma
32 51545 11 127825348 127931093 Gain ETS1 Burkitt''s lymphoma
33 64462 12 128465362 132449811 Gain Burkitt''s lymphoma
34 67044 12 35400000 132349534 Insertion Burkitt''s lymphoma
35 70408 12 61724591 82263925 Gain Burkitt''s lymphoma
36 74099 13 100500000 109100000 Insertion Burkitt''s lymphoma
37 74289 13 103640000 112610000 Loss ANKRD10 Burkitt''s lymphoma
38 74290 13 103640000 112610000 Loss ARHGEF7 Burkitt''s lymphoma
39 74291 13 103640000 112610000 Loss COL4A1 Burkitt''s lymphoma
40 74292 13 103640000 112610000 Loss COL4A2 Burkitt''s lymphoma
41 74293 13 103640000 112610000 Loss EFNB2 Burkitt''s lymphoma
42 74294 13 103640000 112610000 Loss ERCC5 Burkitt''s lymphoma
43 74295 13 103640000 112610000 Loss FGF14 Burkitt''s lymphoma
44 74296 13 103640000 112610000 Loss ING1 Burkitt''s lymphoma
45 74297 13 103640000 112610000 Loss IRS2 Burkitt''s lymphoma
46 74298 13 103640000 112610000 Loss LIG4 Burkitt''s lymphoma
47 74299 13 103640000 112610000 Loss PCCA Burkitt''s lymphoma
48 74300 13 103640000 112610000 Loss RAB20 Burkitt''s lymphoma
49 74301 13 103640000 112610000 Loss SLC10A2 Burkitt''s lymphoma
50 74302 13 103640000 112610000 Loss TNFSF13B Burkitt''s lymphoma

Expression for Burkitt Lymphoma

Search GEO for disease gene expression data for Burkitt Lymphoma.

Pathways for Burkitt Lymphoma

Pathways related to Burkitt Lymphoma according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

GO Terms for Burkitt Lymphoma

Cellular components related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40 CD40LG CXCR5 MS4A1

Biological processes related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 CD40 CD40LG CR2 CXCL13 CXCR5
2 regulation of cell proliferation GO:0042127 9.73 BCL6 CCND3 CD40 CXCL13
3 regulation of immune response GO:0050776 9.67 BCL6 CD40 CD40LG SH2D1A
4 positive regulation of endothelial cell apoptotic process GO:2000353 9.51 CD40 CD40LG
5 isotype switching GO:0045190 9.49 AICDA CD40LG
6 hypothalamus development GO:0021854 9.48 BAX MYC
7 humoral immune response GO:0006959 9.46 IFNA1 MS4A1 PAX5 SH2D1A
8 B cell activation GO:0042113 9.43 CD40 CXCR5 MS4A1
9 germinal center formation GO:0002467 9.4 BCL6 CXCL13
10 B cell differentiation GO:0030183 9.35 AICDA BCL6 CD40LG CR2 IFNA1
11 regulation of immunoglobulin secretion GO:0051023 9.32 CD40 CD40LG
12 B cell proliferation GO:0042100 9.02 CD40 CD40LG CR2 IFNA1 MS4A1

Molecular functions related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 8.92 MYBL1 MYC PAX5 SOX11

Sources for Burkitt Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....